Alba Somovilla

Dr. Alba Somovilla

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in COVID
Verified
Journal Article
Open access
PDF file
MGMarta Domínguez Gallego
Marta Domínguez Gallego
PBPaula Panos Basterra
Paula Panos Basterra
ASAlba Somovilla
Alba Somovilla
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
CRCarmen Ramos
Carmen Ramos
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
Headache is a common symptom during SARS-CoV-2 infection and may persist beyond three months. Both tension-type and migraine-like headaches have been described during SARS-CoV-2 infection and after immunization. The main objective was to characterize headache phenotype during SARS-CoV-2 infection and its relationship with headache recurrence following reinfection and COVID-19 vaccination in a cohort of healthcare professionals. Secondary aims included profiling primary headaches and identifying predictors of post-COVID-19 headache persistence. We included 109 participants (86.2% women, mean age 45.3 ± 2.5 years). During infection, 49.5% met ICHD-3 criteria for tension-type headache and 12.8% for migraine. Headache recurred in 62.5% after reinfection and 59.2% after vaccination. A primary-headache history was present in 77.9% of sampled patients (25.9% migraine, 47.1% tension-type). The COVID-19 headache phenotype typically mirrored patients’ previous headache type during reinfection and post-vaccination. Persistent headache beyond three months from SARS-CoV-2 infection occurred in 22.9% and was associated with fibromyalgia and obesity. These findings suggest that COVID-19-related headache often mirrors the patient’s pre-existing primary headache and tends to recur with the same phenotype following reinfection or vaccination.

21 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMarta Domínguez Gallego
Marta Domínguez Gallego
PBPaula Panos Basterra
Paula Panos Basterra
ASAlba Somovilla
Alba Somovilla
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
CRCarmen Ramos
Carmen Ramos
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
Background: Headache is a common symptom during SARS-CoV-2 infection that can persist beyond three months. Both tension-type and migraine-like headaches have been described during SARS-CoV-2 infection and immunization. Objective: The main objective is to characterize the headache phenotype during SARS-CoV-2 infection and to examine its relationship with headache recurrence following reinfection and COVID-19 vaccination. As secondary endpoints, we evaluated the characteristics of primary headache according to the COVID-19 headache profile and studied potential predictors of persistent headache following COVID-19. Results: 109 patients were included, 86.2% women, mean age 45.3 years (SD: 2.5). COVID-19 headache met the International Classification of Headache Disorders (ICHD-3) criteria for tension-type headache in 49.5% (54/109) and for migraine in 12.8% (14/109). Headache recurrence occurred in 62.5% (15/24) of patients upon reinfection and in 59.2% (61/103) following vaccination. Among all participants, 77.9% (85/109) had a prior diagnosis of primary headache: 25.9% (22/85) with migraine and 47.1% (40/85) with tension-type. The phenotype of COVID-19 headache (migraine-like or tension-type) tended to resemble the patient's pre-existing headache pattern during both reinfection and after vaccination. Additionally, 22.9% (25/109) experienced post-COVID-19 headache, which was associated with fibromyalgia and obesity. Conclusions: Our findings suggest that the COVID-19 headache profile is closely related to the patient's pre-existing primary headache and is associated with reinfection and post-vaccination.

25 June 2026 in Brain and Behavior
Verified
Journal Article
Open access
ASAlba Somovilla
Alba Somovilla
IFIris Fernández‐Lázaro
Iris Fernández‐Lázaro
JPJosué Pagán
Josué Pagán
DSDaniel Saiz
Daniel Saiz
JDJavier Díaz‐De‐Terán
Javier Díaz‐De‐Terán
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
Background: Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence. This study evaluated their safety and effectiveness in patients treated for ≥2 years. Methods: This multicenter retrospective study included patients from 13 headache units who received the same anti‐CGRP antibody for ≥24 months, excluding discontinuation periods. Baseline characteristics, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were recorded at baseline, 6 months, 1, 2, 3, and 4 years. Descriptive statistics were used to summarize clinical characteristics, and appropriate parametric or non‐parametric tests were applied for group comparisons. Multivariate analyses were performed to explore associations between baseline variables and long‐term treatment response. Results: A total of 454 patients (91% female, mean age 48) were analyzed, with follow‐up at 2 years ( n = 454), 3 years ( n = 135), and 4 years ( n = 17). Treatments included erenumab (39%), galcanezumab (34%), and fremanezumab (27%). Fifty‐seven percent maintained continuous therapy, while 43% restarted after discontinuation. Sustained reductions in MHD and MMD were observed at 2, 3, and 4 years (MHD from 20 to 6, 6, 5/MMD from 14 to 4, 4, and 2). Medication overuse decreased from 78% to 13%, 20%, and 18%. Loss of effectiveness occurred in 4.2% after 2 years. AEs appeared in 80%), leading to discontinuation in 0.4%. Multivariate analysis showed that shorter disease duration prior to anti‐CGRP initiation, earlier anti‐CGRP initiation, and greater MHD/MMD reduction at 6 months were associated with better long‐term outcomes. Conclusions: Anti‐CGRP mAbs demonstrate sustained long‐term safety and effectiveness, with consistent reduction in headache and migraine days and lower medication overuse. Early initiation and greater initial improvement predict better long‐term outcomes. Findings support extending therapy beyond 12–18 months, supporting optimization of clinical protocols.